Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
December 15 2020 - 4:53PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
SEC File Number 000-25169
NOTIFICATION OF LATE FILING
(Check One): ¨Form
10-K ¨ Form 20-F ¨ Form 11-K
x Form 10-Q ¨ Form 10-D ¨
Form N-SAR ¨ Form N-CSR
For Period Ended: October 31, 2020
¨
Transition Report on Form 10-K
¨
Transition Report on Form 20-F
¨
Transition Report on Form 11-K
¨
Transition Report on Form 10-Q
¨
Transition Report on Form N-SAR
For the Transition Period Ended: ________________________
Nothing in this form shall be construed to imply
that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify the item(s) to which the notification relates:
PART I -- REGISTRANT INFORMATION
Generex Biotechnology Corporation
Full Name of Registrant
Former Name if Applicable
10102 USA TODAY WAY
Address of Principal Executive Office (Street and Number)
Miramar, Florida 33025
City, State and Zip Code
PART II -- RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort
or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)
|
(a)
|
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
[X]
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
(c)
|
The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III-- NARRATIVE
State below in reasonable detail why the Form 10-K, 20-F, 11-K,
10-Q, 10-D, N-SAR, N-CSR or the transition report portion thereof, could not be filed within the prescribed time period. (Attach
extra sheets if needed.)
Generex Biotechnology Corporation (the “Company”) has
been unable to complete its Form 10-Q for the fiscal quarter ended October 31, 2020, within the prescribed time period because
of delays in completing the preparation of its financial statements and its management discussion and analysis. Such delays are
primarily due to the Company’s management’s dedication of such management's time to business matters. The Company intends
to file its Form 10-Q within the 5-day extension period afforded by SEC Rule 12b-25 under the Securities Exchange Act of 1934,
as amended. The Company is in the process of preparing its financial information as well as completing the required review.
PART IV -- OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to
this notification
Anthony S. Crisci
|
|
914
|
|
417-9706
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
(2) Have all other periodic reports required under Section 13
or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12
months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no,
identify report(s).
☒ Yes ☐No
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in
the subject report or portion thereof?
☐ Yes ☒ No
If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
Generex Biotechnology Corporation
(Name of Registrant as Specified in Charter)
Has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: December 15, 2020
|
|
By: /s/ Mark Corrao
|
|
|
Mark Corrao
|
|
|
Chief Financial Officer
|
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Aug 2023 to Aug 2024